Bridgebio Pharma, INC 8-K filings

BridgeBio Pharma announced robust second quarter 2026 financial results, showcasing significant revenue growth and key regulatory milestones for its promising drug candidates.

BridgeBio Pharma announced the FDA has accepted its New Drug Application for encaleret to treat Autosomal Dominant Hypocalcemia Type 1 (ADH1), with a PDUFA target action date of May 8, 2027.

BridgeBio Pharma announced a $1 billion preferred equity financing led by Sixth Street and HealthCare Royalty to fund upcoming product launches and growth initiatives.

BridgeBio Pharma shareholders approved all proposals at the 2026 Annual Meeting, including an increase in shares for the incentive plan.

BridgeBio Pharma announced the FDA has accepted its New Drug Application for BBP-418 with Priority Review for LGMD2I/R9, setting a target action date of November 27, 2026.

BridgeBio Pharma, Inc. announced an at-the-market equity offering program to sell up to $500 million of its common stock.

BridgeBio Pharma reported strong Q1 2026 revenue growth driven by Attruby, alongside a new $500 million stock repurchase program authorization.

BridgeBio submitted an NDA to the FDA for BBP-418 in LGMD2I/R9 after Phase 3 interim data met all endpoints, targeting a late 2026/early 2027 U.S. launch if approved.

BridgeBio Pharma announced robust fourth quarter and full year 2025 financial results, driven by Attruby sales and positive Phase 3 trial readouts for three pipeline assets.

BridgeBio Pharma announced positive Phase 3 topline results for oral infigratinib, showing statistically significant improvements in height velocity and body proportionality in children with achondroplasia.

BridgeBio Pharma successfully priced and issued $632.5 million in 0.75% convertible senior notes due 2033, aiming to refinance existing debt, extend maturity, and reduce dilution.

BridgeBio Pharma announced preliminary Q4 and full-year 2025 financial results, significant commercial progress for Attruby, and positive clinical and regulatory updates across its late-stage pipeline.

BridgeBio Pharma, Inc. announced positive topline results from its Phase 3 CALIBRATE study of encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1), meeting all primary and key secondary endpoints.

BridgeBio Pharma announced robust third-quarter 2025 financial results and significant positive clinical trial outcomes for multiple pipeline programs.

BridgeBio Pharma reports positive topline results from its FORTIFY Phase 3 study of BBP-418 for limb-girdle muscular dystrophy type 2I/R9, meeting all primary and secondary endpoints.

BridgeBio Pharma announced robust second-quarter 2025 financial results, driven by accelerating Attruby sales and significant progress in multiple late-stage clinical trials for genetic diseases.

BridgeBio Pharma, Inc. and its subsidiary Eidos Therapeutics, Inc. have entered into an agreement to sell certain European royalty rights for acoramidis for $300 million in cash.

BridgeBio Pharma, Inc. announced that its stockholders approved key corporate governance changes, including an amendment to limit officer liability and an expansion of its equity incentive plan, at its 2025 Annual Meeting.

BridgeBio announces first quarter 2025 financial results, highlighted by $36.7 million in Attruby net product revenue and advancements in key pipeline programs.

BridgeBio Pharma announces the appointment of Thomas Trimarchi as President and CFO, succeeding Brian Stephenson who is departing for personal reasons and will transition to a consulting role.

BridgeBio Pharma successfully prices a $500 million convertible senior notes offering to refinance existing debt and for general corporate purposes.

BridgeBio Pharma announces its Q4 and full year 2024 financial results, highlighting the successful launch of Attruby and advancements in its clinical pipeline.

BridgeBio Pharma reports strong early demand for Attruby, completion of enrollment for three Phase 3 trials, and a solid financial position to support upcoming milestones.

BridgeBio's Attruby (acoramidis) has been approved by the FDA for treating ATTR-CM, demonstrating a significant reduction in cardiovascular death and related hospitalizations.

BridgeBio Pharma announced positive clinical trial results for acoramidis, progress in its late-stage pipeline, and its financial results for the third quarter of 2024.

BridgeBio Pharma announced positive topline results from its Phase 1/2 trial of BBP-631 gene therapy for Congenital Adrenal Hyperplasia (CAH), showing increased cortisol production, but will not pursue further development due to financial constraints.

BridgeBio Pharma has entered into a joint venture, GondolaBio, with a group of investors, securing $300 million in committed financing to advance its early-stage clinical and pre-clinical programs.

BridgeBio Pharma announced positive clinical trial results for several key programs and reported its second quarter 2024 financial results, highlighting progress towards commercialization and pipeline advancement.

BridgeBio Pharma has appointed Thomas Trimarchi as President and Chief Operating Officer, effective July 23, 2024, as part of a leadership restructuring.

BridgeBio Pharma's stockholders approved the amendment and restatement of the 2021 Stock Option and Incentive Plan, increasing the number of shares reserved for issuance, and elected five directors at their annual meeting on June 21, 2024.